5DQE

Crystal structure of human transcription factor TEAD2 in complex with bromo-fenamic acid

• PDB DOI:  https://doi.org/10.2210/pdb5DQE/pdb

• Classification: TRANSCRIPTION
• Organism(s): Homo sapiens
• Expression System: Escherichia coli BL21(DE3)
• Mutation(s): No 


• Deposited: 2015-09-14 Released: 2015-11-25 
• Deposition Author(s): Han, X., Luo, X.
• Funding Organization(s): National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)

---

Experimental Data Snapshot

• Method: X-RAY DIFFRACTION
• Resolution: 2.18 Å
• R-Value Free: 0.227 
• R-Value Work: 0.179 
• R-Value Observed: 0.181 

Literature

Targeting the Central Pocket in Human Transcription Factor TEAD as a Potential Cancer Therapeutic Strategy.

Pobbati, A.V., Han, X., Hung, A.W., Weiguang, S., Huda, N., Chen, G.Y., Kang, C., Chia, C.S., Luo, X., Hong, W., Poulsen, A.

(2015) Structure 23: 2076-2086

• PubMed: 26592798 
• DOI: https://doi.org/10.1016/j.str.2015.09.009
• Primary Citation of Related Structures:  
  5DQ8, 5DQE


• PubMed Abstract: 
  

The human TEAD family of transcription factors (TEAD1-4) is required for YAP-mediated transcription in the Hippo pathway. Hyperactivation of TEAD's co-activator YAP contributes to tissue overgrowth and human cancers, suggesting that pharmacological interference of TEAD-YAP activity may be an effective strategy for anticancer therapy. Here we report the discovery of a central pocket in the YAP-binding domain (YBD) of TEAD that is targetable by small-molecule inhibitors. Our X-ray crystallography studies reveal that flufenamic acid, a non-steroidal anti-inflammatory drug (NSAID), binds to the central pocket of TEAD2 YBD. Our biochemical and functional analyses further demonstrate that binding of NSAIDs to TEAD inhibits TEAD-YAP-dependent transcription, cell migration, and proliferation, indicating that the central pocket is important for TEAD function. Therefore, our studies discover a novel way of targeting TEAD transcription factors and set the stage for therapeutic development of specific TEAD-YAP inhibitors against human cancers.

---

Organizational Affiliation: 

Experimental Therapeutics Centre, A(∗)STAR, 31 Biopolis Way, #3-01, Singapore 138669, Singapore. Electronic address: [e-mail].

Biological Assembly 1  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 1 assigned by authors and generated by PISA (software)

Biological Assembly 2  

Global Symmetry: Asymmetric - C1 
Global Stoichiometry: Monomer - A1 

Biological assembly 2 assigned by authors and generated by PISA (software)

Macromolecule Content

• Total Structure Weight: 55.85 kDa 
• Atom Count: 3,459 
• Modelled Residue Count: 401 
• Deposited Residue Count: 480 
• Unique protein chains: 1

Macromolecules

Entity ID: 1
Molecule	Chains	Sequence Length	Organism	Details	Image
Transcriptional enhancer factor TEF-4	A, B	240	Homo sapiens	Mutation(s): 0  Gene Names: TEAD2, TEF4
UniProt & NIH Common Fund Data Resources
Find proteins for Q15562 (Homo sapiens) Explore Q15562  Go to UniProtKB:  Q15562
PHAROS:  Q15562

Small Molecules

Ligands 1 Unique
ID	Chains	Name / Formula / InChI Key	2D Diagram
5E4	C [auth A], D [auth B], E [auth B]	2-[(3-bromophenyl)amino]benzoic acid C13 H10 Br N O2 IRGQJNUPNQPHQP-UHFFFAOYSA-N

Experimental Data & Validation

Experimental Data

• Method: X-RAY DIFFRACTION
• Resolution: 2.18 Å
• R-Value Free: 0.227 
• R-Value Work: 0.179 
• R-Value Observed: 0.181 
• Space Group: C 1 2 1

Unit Cell:

Length ( Å )	Angle ( ˚ )
a = 121.47	α = 90
b = 61.582	β = 117.7
c = 80.419	γ = 90

Software Package:

Software Name	Purpose
PHENIX	refinement
HKL-3000	phasing
PHASER	phasing
HKL-3000	data reduction
HKL-3000	data scaling

Structure Validation

Entry History & Funding Information

Deposition Data

• Released Date: 2015-11-25 
Deposition Author(s): Han, X., Luo, X.

---

Funding Organization	Location	Grant Number
National Institutes of Health/National Institute of General Medical Sciences (NIH/NIGMS)	United States	5R01GM107415

Revision History  

• Version 1.0: 2015-11-25
  Type: Initial release
  
• Version 1.1: 2017-09-20
  Changes: Author supporting evidence, Database references, Derived calculations, Refinement description
• Version 1.2: 2018-05-16
  Changes: Data collection, Database references
• Version 1.3: 2019-12-25
  Changes: Author supporting evidence
• Version 1.4: 2023-09-27
  Changes: Data collection, Database references, Refinement description